Recent advances in nanotechnology may offer a new hope for a significant improvement and success of cancer treatment, especially in preventing tumor growth and progression. This is particularly relevant to brain gliomas that have very poor prognosis, are largely incurable by current therapy, and therefore, need novel treatment modalities. Our research is dealing with a new nanoscale (20-30 nm) anti-tumor drug delivery system (Polycefin) based on naturally derived nanoplatform, poly(p-L-malic acid) (PMLA) fi-om a slime mold, Physarum polycephalum. This universal platform may be easily modified to include new moieties covalently attached to PMLA backbone, such as anti-cancer drugs inhibiting tumor cell targets. The current version of the delivery platform contains: biodegradable, non-toxic, and non-immunogenic PMLA;a drug releasing unit;Morpholino antisense oligonucleotide (AON) unit targeting two chains of angiogenic glioma-increased protein laminin 411;anti-transferrin receptor antibody for specific tissue targeting and endosomal uptake;biopolymer protector polyethylene glycol (PEG);a hydrophobic release unit for endosomal membrane disruption;and a fluorescent tracking dye. The nanoplatform was developed to inhibit the synthesis of complex proteins with systemic delivery. These proteins, such as trimeric laminins play a significant role in tumor growth, invasion and metastasis, but previously could not be blocked because by conventional drugs. Preliminary data demonstrated drug delivery directly to the brain tumor site, inhibition of glioma molecular targets (laminin chains), and lack of visible toxicity in vivo. As a result, a 60% increase in survival of glioma bearing animals (p<0.01) with 10-fold tumor size reduction (p<0.01) was achieved. This I.V. systemic delivery system will be evaluated and developed in this proposal. The project will focus on the preclinical testing of basic nanoconjugate platform containing AON against our characterized glioma marker, laminin 411, a protein important for tumor vessel development. The ultimate goal is to select a lead vehicle-drug compound from several polymer-based conjugates by detailed chemical, chemical-physical and preclinical evaluation, which would establish a solid rationale for clinical usage.
Our Aims i nclude (1) chemical optimization of Polycefin variants for the most efficient blocking of laminin 411 by varying the number of AON and targeting antibody molecules;(2) chemical, physical and pharmacokinetic characterization of the platform including studies of stability, in vivo half-life and tissue accumulation;(3) optimization of the number of injections and dosage for the most effective tumor treatment;and (4) GLP-compliant study of drug pharmacological properties (toxicity, distribution, metabolism and excretion).

Public Health Relevance

This project is relevant to the NIH announcement RFA-CA-05-026 "Cancer Nanotechnology Platform Partnerships" (UOl). Our multidisciplinary team created a new nanoscale (20-30 lun) anti-tumor drug delivery system based on poly(P-L-malic acid) (PMLA). This universal platform may IK easily modified to include new moieties covalently attached to PMLA backbone, such as anti-cancer drugs inhibiting tumor cell targets. This is particularly relevant to brain gliomas that have very poor prognosis, are largely incurable by current therapy, and therefore, need novel treatment modalities. The nanoplatform was developed to inhibit the synthesis of several tumor specific targets that play a significant role in tumor growth, invasion and metastasis, but previously could not be blocked by conventional drugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA151815-05
Application #
8703510
Study Section
Special Emphasis Panel (ZCA1-SRLB-X (M1))
Program Officer
Farrell, Dorothy F
Project Start
2010-08-25
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
5
Fiscal Year
2014
Total Cost
$457,921
Indirect Cost
$180,393
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Hsu, Bryan B; Hagerman, Samantha R; Jamieson, Kelsey et al. (2014) Multilayer films assembled from naturally-derived materials for controlled protein release. Biomacromolecules 15:2049-57
Hsu, Bryan B; Jamieson, Kelsey S; Hagerman, Samantha R et al. (2014) Ordered and kinetically discrete sequential protein release from biodegradable thin films. Angew Chem Int Ed Engl 53:8093-8
Ljubimova, Julia Y; Ding, Hui; Portilla-Arias, Jose et al. (2014) Polymalic acid-based nano biopolymers for targeting of multiple tumor markers: an opportunity for personalized medicine? J Vis Exp :
Lanz-Landázuri, Alberto; Portilla-Arias, José; Martínez de Ilarduya, Antxon et al. (2014) Nanoparticles of esterified polymalic acid for controlled anticancer drug release. Macromol Biosci 14:1325-36
Ding, Hui; Portilla-Arias, Jose; Patil, Rameshwar et al. (2013) Distinct mechanisms of membrane permeation induced by two polymalic acid copolymers. Biomaterials 34:217-25
Ljubimova, Julia Y; Portilla-Arias, Jose; Patil, Rameshwar et al. (2013) Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment. J Drug Target 21:956-67